132 related articles for article (PubMed ID: 15504857)
1. Potential for interactions between caspofungin and nelfinavir or rifampin.
Stone JA; Migoya EM; Hickey L; Winchell GA; Deutsch PJ; Ghosh K; Freeman A; Bi S; Desai R; Dilzer SC; Lasseter KC; Kraft WK; Greenberg H; Waldman SA
Antimicrob Agents Chemother; 2004 Nov; 48(11):4306-14. PubMed ID: 15504857
[TBL] [Abstract][Full Text] [Related]
2. Lack of pharmacokinetic drug interaction between oral posaconazole and caspofungin or micafungin.
Krishna G; Vickery D; Ma L; Yu X; Noren C; Power E; Beresford E; Medlock M
J Clin Pharmacol; 2011 Jan; 51(1):84-92. PubMed ID: 20489029
[TBL] [Abstract][Full Text] [Related]
3. Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations.
Mistry GC; Migoya E; Deutsch PJ; Winchell G; Hesney M; Li S; Bi S; Dilzer S; Lasseter KC; Stone JA
J Clin Pharmacol; 2007 Aug; 47(8):951-61. PubMed ID: 17660480
[TBL] [Abstract][Full Text] [Related]
4. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
[TBL] [Abstract][Full Text] [Related]
5. Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use.
Bergshoeff AS; Wolfs TF; Geelen SP; Burger DM
Ann Pharmacother; 2003 Apr; 37(4):521-5. PubMed ID: 12659608
[TBL] [Abstract][Full Text] [Related]
6. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.
Stone JA; Holland SD; Wickersham PJ; Sterrett A; Schwartz M; Bonfiglio C; Hesney M; Winchell GA; Deutsch PJ; Greenberg H; Hunt TL; Waldman SA
Antimicrob Agents Chemother; 2002 Mar; 46(3):739-45. PubMed ID: 11850256
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.
Walsh TJ; Adamson PC; Seibel NL; Flynn PM; Neely MN; Schwartz C; Shad A; Kaplan SL; Roden MM; Stone JA; Miller A; Bradshaw SK; Li SX; Sable CA; Kartsonis NA
Antimicrob Agents Chemother; 2005 Nov; 49(11):4536-45. PubMed ID: 16251293
[TBL] [Abstract][Full Text] [Related]
8. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
[TBL] [Abstract][Full Text] [Related]
9. Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes.
Moody DE; Fang WB; Lin SN; Weyant DM; Strom SC; Omiecinski CJ
Drug Metab Dispos; 2009 Dec; 37(12):2323-9. PubMed ID: 19773542
[TBL] [Abstract][Full Text] [Related]
10. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.
Fang AF; Damle BD; LaBadie RR; Crownover PH; Hewlett D; Glue PW
Pharmacotherapy; 2008 Jan; 28(1):42-50. PubMed ID: 18154473
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants.
Migoya EM; Mistry GC; Stone JA; Comisar W; Sun P; Norcross A; Bi S; Winchell GA; Ghosh K; Uemera N; Deutsch PJ; Wagner JA
J Clin Pharmacol; 2011 Feb; 51(2):202-11. PubMed ID: 20679501
[TBL] [Abstract][Full Text] [Related]
13. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
Wenning LA; Hanley WD; Brainard DM; Petry AS; Ghosh K; Jin B; Mangin E; Marbury TC; Berg JK; Chodakewitz JA; Stone JA; Gottesdiener KM; Wagner JA; Iwamoto M
Antimicrob Agents Chemother; 2009 Jul; 53(7):2852-6. PubMed ID: 19433563
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment.
Calcagno A; Baietto L; Pagani N; Bertucci R; Rostagno R; D'Avolio A; Di Perri G; De Rosa FG
Scand J Infect Dis; 2013 Nov; 45(11):882-4. PubMed ID: 23796067
[TBL] [Abstract][Full Text] [Related]
15. Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion.
Kirby BJ; Collier AC; Kharasch ED; Whittington D; Thummel KE; Unadkat JD
Drug Metab Dispos; 2012 Mar; 40(3):610-6. PubMed ID: 22190694
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects.
Dimmitt DC; Cramer MB; Keung A; Arumugham T; Weir SJ
Cancer Chemother Pharmacol; 1999; 43(2):126-32. PubMed ID: 9923817
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of caspofungin in older infants and toddlers.
Neely M; Jafri HS; Seibel N; Knapp K; Adamson PC; Bradshaw SK; Strohmaier KM; Sun P; Bi S; Dockendorf MF; Stone JA; Kartsonis NA
Antimicrob Agents Chemother; 2009 Apr; 53(4):1450-6. PubMed ID: 19114680
[TBL] [Abstract][Full Text] [Related]
18. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.
Naesens M; Kuypers DR; Streit F; Armstrong VW; Oellerich M; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2006 Nov; 80(5):509-21. PubMed ID: 17112807
[TBL] [Abstract][Full Text] [Related]
19. Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.
Boffito M; Pozniak A; Kearney BP; Higgs C; Mathias A; Zhong L; Shah J
Antimicrob Agents Chemother; 2005 Oct; 49(10):4386-9. PubMed ID: 16189129
[TBL] [Abstract][Full Text] [Related]
20. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide.
Park JY; Kim KA; Park PW; Park CW; Shin JG
Clin Pharmacol Ther; 2003 Oct; 74(4):334-40. PubMed ID: 14534520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
